GlassScriptPhysician profile
Jennifer E Abdalla
NPI 1376004937
$3,628.12
in general payments reported to CMS, 2019-2025
16 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $747 · 2023: $712 · 2024: $691 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,026.46 | 2022-2025 | |
| Amgen INC. | $604.82 | 2021-2025 | Krystexxa, Tavneos, Uplizna |
| Astrazeneca Pharmaceuticals LP | $523.30 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $257.10 | 2024-2025 | |
| Abbvie INC. | $208.99 | 2022-2025 | Rinvoq |
| Teva Pharmaceuticals USA, INC. | $173.26 | 2023 | Austedo, Austedo Xr |
| Glaxosmithkline, LLC. | $171.02 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $132.67 | 2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.69 | 2021 | |
| Ucb, INC. | $108.41 | 2022-2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $95.30 | 2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $55.81 | 2025 | Tremfya |
| Janssen Biotech, INC. | $55.59 | 2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $45.49 | 2022 | |
| Sobi, INC | $33.34 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $27.87 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.